 Subjects will undergo an induction regimen consisting of 1 cycle of cytarabine 3 gmm2 Intravenously over 1 hour every 12 hours for 8 total doses and mitoxantrone 10 mgm2d intravenously IV over 30 minutes daily on days 1, 2, and 3. This will be combined with Alemtuzumab anti-CD52 antibody for 6-8 weeks. If, after this one cycle, subjects have not had progression of disease as noted on physical exam or radiographic scans, they will proceed to stem cell mobilization with cyclophosphamide. This will be immediately followed by high dose therapy with stem cell support. Following count recovery, rituximab will be used for 8 total doses as consolidation therapy. Involved field irradiation may be given post-transplant to those with localized bulky disease as well. Day -6: Carmustine BCNU: 15 mgkg or 550 mgm2 IV over 2 hrs. Day -4: Etoposide Day -2: Cyclophosphamide 100 mgkg in 1 liter D5W over 2 hours. 